Healthcare Stocks

Imugene Limited (ASX:IMU) Progressing with PD1-Vaxx Phase I Trial

 Imugene Limited (ASX:IMU) Progressing with PD1-Vaxx Phase I Trial

Summary Imugene Limited (ASX:IMU) completes the enrolment of three patients under the first cohort under PD1-Vaxx Phase I clinical trial. Following the Phase I trial, a monotherapy optimal biological dose will be determined through a review by ...

Read More...
Imugene’s Shares zoomed up by 17.65% on the declaration of Half-year results

Imugene’s Shares zoomed up by 17.65% on the declaration of Half-year results

Imugene Limited (ASX: IMU) has released its half-year results ended 31 December 2018. As at 31 December 2018, the group recorded a loss for half-year $3,449,097 (2017: $1,632,852). The loss in the business from the comparative period was caused by th...

Read More...
Imugene Reported Cancer Research Publishing In The Prestigious American Journal

Imugene Reported Cancer Research Publishing In The Prestigious American Journal

Imugene Limited (ASX: IMU), which is in the business of clinical stage immuno-oncology, IS building up a range of new and novel immunotherapies that try to activate the immune system of malignancy patients to treat tumors. The company?s extraordinary...

Read More...
Imugene Rebounds On Receiving Tax Rebate And Advancement To Phase 2 In Gastric Cancer Trial

Imugene Rebounds On Receiving Tax Rebate And Advancement To Phase 2 In Gastric Cancer Trial

Imugene Limited (ASX: IMU), the immuno-oncology company, with its unique technological platform basically tries to harness the immune system of the cancer patients and helps in the generation of the antibodies that can fight against tumors and comple...

Read More...
Ad

GET A FREE STOCK REPORT

Top Penny Picks under 20 Cents to Fit Your Pocket! Get Exclusive Report on Penny Stocks For FREE Now.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK